<DOC>
	<DOC>NCT00372424</DOC>
	<brief_summary>This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment in the advanced disease setting.</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease. Tumors overexpressing Her2 Candidate for treatment with docetaxel/trastuzumab Histology of inflammatory carcinoma AST and/or ALT &gt;1.5 x ULN concomitant with ALP &gt;2.5 x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast cancer over-expressing HER2. First-line treatment with sunitinib/docetaxel/trastuzumab.</keyword>
</DOC>